Molnupiravir (Movfor) 200 mg – 40 Tablets
USD $84.75 Add to cart

Molnupiravir (Movfor) 200 mg – 40 Tablets

USD $84.75

Each capsule of Movfor contains 200 mg of Molnupiravir and comes 40 capsules per bottle. It is used in treating COVID-19 infected by SAR-CoV-2.

Active Ingrediant: Molnupiravir
Generic Name: Movfor
Strength: 200 mg
Dosage Type: Tablets
Packaging Type: Capsule in bottle
Contains: 40 Tablets

Examples of Packages sent

Molnupiravir Information

What is this drug used for?

  • It is used to treat COVID-19 in those infected by SARS-CoV-2.

Adverse Effects

1-10%

  • Diarrhea (2%)
  • Nausea (1%)
  • Dizziness (1%)

≤2%

  • Selected Grade 3 and 4 laboratory abnormalities in chemistry (ALT, AST, creatinine, and lipase) and hematology (hemoglobin, platelets, and leukocytes)

Cautions

  • There are limited clinical data available; serious and unexpected adverse events may occur that have yet to be reported.
  • May cause fetal harm when administered to pregnant females.

Bone and cartilage toxicity

  • Not authorised for use in patients aged <18 years owing to possible effects on bone and cartilage growth
  • Bone and cartilage toxicity was observed in rats after repeated dosing
  • Safety and efficacy have not been established in pediatric patients

Pregnancy

  • Not recommended during pregnancy

Dosage Modifications

Renal impairment

  • Mild or moderate (eGFR >30 mL/min): No dosage adjustment necessary
  • Severe (eGFR <30 mL/min), end-stage renal disease, or patients on dialysis: Pharmacokinetics not evaluated; not expected to have a significant effect on NHC (N4-hydroxycytidine) exposure

Hepatic impairment

  • Mild to severe (Child-Pugh Class A to C): No dosage adjustment required
  • Preclinical data indicate that hepatic elimination is not expected to be a major route of NHC elimination

Dosing Considerations

Verify pregnancy status in females of childbearing potential before initiating

Limitations of use

  • Not authorised for use in patients aged <18 years
  • Not authorised for initiation of treatment in patients requiring hospitalization owing to COVID-19
  • Not authorised for use for >5 consecutive days
  • Not authorised for preexposure or postexposure prophylaxis for prevention of COVID-19

Administration

Oral Administration

Take orally, with or without food

Missed dose

  • <10 hours: Take missed dose as soon as possible, and resume normal dosing schedule
  • >10 hours: Skip dose, and take the next dose at the regularly scheduled time
  • Do not double dose to make up for missed dose

Storage

Store at 20-25ºC (68-77ºF); excursions permitted to 15-30ºC (59-86ºF)

Brand

Molulife

Additional information

Strength

Packaging Type

Generic Name

Dosage Type

Active Ingrediant